Atox Bio

Company Overview

Snapshot

Founded in May 2003 by Gila Arad and Raymond Kaempfer, Atox Bio operated with 11–50 employees. The company raised a total of $64.85 million across 5 funding rounds from 10 investors. A significant milestone was the FDA's acceptance to file the New Drug Application (NDA) for Reltecimod in December 2020, aimed at treating suspected organ dysfunction or failure in patients with necrotizing soft tissue infection.

Business overview

Atox Bio was a late-stage biotechnology company focused on developing novel immunomodulators for critically ill patients. Its core product, Reltecimod, was designed to treat necrotizing soft-tissue infection (NSTI), a rare and life-threatening condition for which no specific therapy existed. The company operated within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, targeting patients and healthcare providers in the United States.

Strategic signal

In May 2022, Atox Bio ceased operations after the FDA requested an additional clinical trial for its lead product. This event signals the significant regulatory hurdles and financial pressures faced by biotechnology companies, particularly those developing treatments for rare diseases, where extensive clinical validation is required. For investors, it underscores the inherent risks in late-stage drug development and the critical impact of regulatory decisions on a company's viability.

Company Intelligence Q&A

What was the primary reason for Atox Bio ceasing operations?

Atox Bio ceased operations in May 2022 following a request from the FDA for an additional clinical trial for its lead product, Reltecimod, which ultimately led to the company's closure.

What was the key regulatory milestone achieved by Atox Bio for Reltecimod?

In December 2020, the FDA accepted the filing of the New Drug Application (NDA) for Reltecimod. This application was for the treatment of suspected organ dysfunction or failure in patients with necrotizing soft tissue infection.

What were the findings from the Phase 3 ACCUTE trial for Reltecimod?

In July 2020, Atox Bio announced a positive effect of Reltecimod on the resolution of organ dysfunction in the Phase 3 ACCUTE trial for patients with necrotizing soft tissue infection.

Which investors participated in Atox Bio's December 2017 funding round?

In December 2017, Atox Bio received funding from investors including.

What was the purpose of the funding round in July 2014?

In July 2014, Atox Bio closed an investment round with participation from.